Eutilex
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Eutilex is a South Korean biotech, listed on KOSDAQ, that develops cancer immunotherapies, treatments that harness the body's own immune system to fight tumours.
Its pipeline includes cell-and-gene therapies (notably a next-generation CAR-T therapy targeting liver and other solid cancers) and antibody therapies designed to block immune suppression around tumours. Both lead programmes are currently in early-stage clinical trials in Korea.
Summary is AI-generated and may contain errors · figures from DART filings
Alongside its biotech pipeline, Eutilex operates an IT services division, covering system integration, system management, and IT consulting, which it runs in parallel with its drug research and clinical activities.
Eutilex in five facts
What does Eutilex do?
Eutilex is a South Korean biotech, listed on KOSDAQ, that develops cancer immunotherapies, treatments that harness the body's own immune system to fight tumours.
Where is Eutilex listed and in which sector?
Eutilex (Korean name: 유틸렉스) trades under KRX code 263050 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Eutilex?
Its market capitalisation was US$26.7M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Eutilex's latest annual revenue and operating profit?
For fiscal year 2025, Eutilex reported revenue of US$7.8M, an operating loss of US$14.3M and a net loss of US$19.5M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was up 8.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Change of CEOSep 22
- [Amended] Change of CEOAug 31
- [Amended] Supply contract signedSupply contract · Jan 30
- Supply contract signedSupply contract · Jan 16
- Supply contract signedSupply contract · Jan 16
- Share transfer agreement tied to the largest shareholder terminated/cancelledOwnership change · Jan 13
- [Amended] Share transfer agreement that will change the largest shareholderOwnership change · Jan 12